Auxagen plans to complete SBIR phase II studies on wound treatment and file an IND in 2012 or early 2013. The strategies for clinical trials and commercialization of the TGF-β antagonist products are to seek partnerships with large pharmaceutical companies and/or biotech companies and/or investors for clinical trials. Auxagen is currently seeking partners and licensees to develop the TGF-β receptor antagonists into commercial products.